Apixaban is a novel oral anticoagulant which is approved for the management of atrial
fibrillation and venous thromboembolism prophylaxis. There have been concerns regarding …

Background: Current guidelines recommend using direct oral anticoagulants (DOACs) over
warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to …

Background: Oral anticoagulants (OAC) reduce the risk of stroke but impose the risk of
bleeding in patients with atrial fibrillation (AF). In the setting of advanced chronic kidney …

Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney
function. The most common estimate of kidney function employed in clinical practice is …

Importance Direct oral anticoagulants (DOACs) are purported to have fewer drug-drug
interactions than warfarin. However, potential interactions with coprescribed medications are …

Background There is limited evidence on the effectiveness and safety of direct-acting oral
anticoagulants in patients with nonvalvular atrial fibrillation (NVAF) and advanced chronic …

Dr Karl Link when he unexpectedly encountered a frustrated farmer, Ed Carlson, who had
driven 200 miles during a blizzard with a dead cow in the back of his truck. 2 Hemorrhagic …

Atrial fibrillation (AF) and renal insufficiency often coexist and are increasingly prevalent with
advancing age. Both the risk of thromboembolic events and bleeding propensity are higher …

Introduction Patients with end-stage kidney disease requiring maintenance haemodialysis
treatment experience a dramatic cardiovascular morbidity and mortality. Due to the high …

Background Data on the effectiveness and safety of Factor-Xa non-vitamin-K oral
anticoagulants in patients with non-valvular atrial fibrillation (NVAF) and renal disease is …